Phase III KEYNOTE-522 Trial KEYTRUDA #SABCS

Phase III KEYNOTE-522 Trial KEYTRUDA #SABCS

SABCS

3 months
97 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Jay Andersen, MD of Compass Oncology discusses the phase 3 KEYNOTE-522 trial was investigating KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 immunotherapy, in combination with chemotherapy that was designed for patients with TNBC.

 

 

 

 

pembrolizumab, keytruda, phase 3, keynote-522 trial, merck's anti-pd-1 immunotherapy, immunotherapy, patients with tnbc, tnbc

Up Next Autoplay